HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ding Ma Selected Research

Ovarian Neoplasms (Ovarian Cancer)

5/2024Exploratory biomarker analysis in the phase III L-MOCA study of olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer.
1/2023Platelet RNA signature independently predicts ovarian cancer prognosis by deep learning neural network model.
1/2023Platelet RNA enables accurate detection of ovarian cancer: an intercontinental, biomarker identification study.
12/2022Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation.
9/2022Evaluation of the prognostic value of lymphadenectomy for low-grade serous ovarian cancer: A case-control multicenter retrospective study.
9/2022Metagenomic analysis of the microbiome of the upper reproductive tract: combating ovarian cancer through predictive, preventive, and personalized medicine.
1/2022Effectiveness and Safety of Niraparib as Neoadjuvant Therapy in Advanced Ovarian Cancer With Homologous Recombination Deficiency (NANT): Study Protocol for a Prospective, Multicenter, Exploratory, Phase 2, Single-Arm Study.
1/2022Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA).
1/2021Expression of hormone receptors predicts survival and platinum sensitivity of high-grade serous ovarian cancer.
1/2021C/EBPβ promotes poly(ADP-ribose) polymerase inhibitor resistance by enhancing homologous recombination repair in high-grade serous ovarian cancer.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Ding Ma Research Topics

Disease

240Neoplasms (Cancer)
04/2024 - 03/2002
102Ovarian Neoplasms (Ovarian Cancer)
05/2024 - 04/2002
87Uterine Cervical Neoplasms (Cancer of the Cervix)
03/2024 - 08/2003
59Neoplasm Metastasis (Metastasis)
03/2024 - 03/2002
43Breast Neoplasms (Breast Cancer)
04/2024 - 12/2002
41Carcinoma (Carcinomatosis)
03/2024 - 03/2002
25Carcinogenesis
08/2022 - 07/2005
19Triple Negative Breast Neoplasms
03/2024 - 05/2018
14Ovarian Epithelial Carcinoma
06/2023 - 07/2003
13Prostatic Neoplasms (Prostate Cancer)
03/2023 - 06/2007
12Lymphatic Metastasis
04/2024 - 03/2006
10Squamous Cell Carcinoma (Epidermoid Carcinoma)
12/2023 - 08/2005
10Hepatocellular Carcinoma (Hepatoma)
01/2023 - 10/2007
9Inflammation (Inflammations)
03/2024 - 01/2014
9Papillomavirus Infections
01/2020 - 01/2005
9Uterine Cervical Dysplasia
01/2018 - 06/2005
7Hypoxia (Hypoxemia)
01/2022 - 04/2005
7Infections
01/2021 - 09/2005
6Adenocarcinoma
11/2023 - 06/2003
6Leukemia
01/2023 - 06/2007
6Glioblastoma (Glioblastoma Multiforme)
05/2022 - 01/2018
5Endometrial Neoplasms (Endometrial Cancer)
04/2024 - 07/2002
5COVID-19
12/2021 - 01/2021
5Glioma (Gliomas)
11/2021 - 01/2016
5Lymphoma (Lymphomas)
09/2014 - 08/2003
4Pancreatic Neoplasms (Pancreatic Cancer)
01/2023 - 08/2016
4Disease Progression
11/2022 - 01/2014

Drug/Important Bio-Agent (IBA)

70Proteins (Proteins, Gene)FDA Link
01/2024 - 07/2002
35Cisplatin (Platino)FDA LinkGeneric
12/2023 - 09/2002
35Messenger RNA (mRNA)IBA
06/2023 - 07/2002
29Biomarkers (Surrogate Marker)IBA
05/2024 - 06/2003
21RNA (Ribonucleic Acid)IBA
11/2023 - 07/2002
21Paclitaxel (Taxol)FDA LinkGeneric
01/2022 - 01/2003
19Peptides (Polypeptides)IBA
02/2024 - 10/2005
18Small Interfering RNA (siRNA)IBA
10/2018 - 06/2006
16DNA (Deoxyribonucleic Acid)IBA
01/2024 - 04/2002
16Cadherins (E-Cadherin)IBA
04/2020 - 11/2005
15PlatinumIBA
05/2024 - 05/2013
13Hormones (Hormone)IBA
04/2024 - 01/2016
12EnzymesIBA
12/2021 - 11/2004
11Histone Deacetylase InhibitorsIBA
11/2023 - 12/2002
11Caspase 3 (Caspase-3)IBA
01/2018 - 11/2002
10VaccinesIBA
01/2021 - 09/2009
10Interleukin-6 (Interleukin 6)IBA
10/2020 - 05/2013
9Phenobarbital (Luminal)FDA Link
10/2023 - 04/2016
9CytokinesIBA
01/2023 - 01/2009
9MicroRNAs (MicroRNA)IBA
02/2020 - 08/2011
9trichostatin A (A 300)IBA
01/2018 - 09/2005
8Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2022 - 03/2002
8Complementary DNA (cDNA)IBA
02/2015 - 05/2002
7Estrogen ReceptorsIBA
04/2024 - 01/2017
7Therapeutic UsesIBA
01/2024 - 12/2009
7Immune Checkpoint InhibitorsIBA
12/2023 - 01/2018
7Indicators and Reagents (Reagents)IBA
01/2023 - 06/2004
7Phosphotransferases (Kinase)IBA
01/2022 - 01/2005
7theasinensin AIBA
06/2017 - 09/2005
7LigandsIBA
05/2016 - 07/2003
7VimentinIBA
01/2014 - 06/2007
6ElementsIBA
04/2024 - 05/2008
6Matrix Metalloproteinases (MMPs)IBA
02/2020 - 11/2004
6Vascular Endothelial Growth Factor CIBA
04/2019 - 05/2006
6Thymidine KinaseIBA
01/2018 - 12/2003
5Transforming Growth Factor beta (TGF-beta)IBA
01/2023 - 01/2004
5Glucose (Dextrose)FDA LinkGeneric
05/2022 - 08/2005
5ImmunosorbentsIBA
12/2021 - 12/2009
5Progesterone Receptors (Progesterone Receptor)IBA
01/2021 - 02/2015
5Reactive Oxygen Species (Oxygen Radicals)IBA
12/2020 - 02/2008
5Oncogene Proteins (Oncogene Protein)IBA
01/2015 - 01/2013
5SurvivinIBA
12/2013 - 02/2004
5Fibronectins (Fibronectin)IBA
08/2013 - 11/2005
4ChromatinIBA
03/2024 - 01/2017
4CateninsIBA
03/2024 - 01/2014
4Vascular Endothelial Growth Factor Receptor-3 (Flt 4)IBA
02/2024 - 07/2007
4Poly(ADP-ribose) Polymerase InhibitorsIBA
12/2023 - 11/2013
4Estrogens (Estrogen)FDA Link
08/2022 - 12/2002
4Carboplatin (JM8)FDA LinkGeneric
01/2022 - 08/2005
4Proteasome InhibitorsIBA
06/2017 - 10/2008
4Bortezomib (Velcade)FDA Link
06/2017 - 10/2008
4Antisense RNA (Anti-Sense RNA)IBA
08/2007 - 04/2006
4Member 1 Subfamily B ATP Binding Cassette TransporterIBA
01/2007 - 09/2003
4Antisense OligonucleotidesIBA
07/2005 - 04/2002
4Butyric Acid (Butanoic Acid)IBA
01/2005 - 12/2002
3InterferonsIBA
03/2024 - 01/2022
3LipopolysaccharidesIBA
02/2024 - 06/2019
3Histone Deacetylases (Histone Deacetylase)IBA
11/2023 - 10/2005
3VorinostatFDA Link
11/2023 - 11/2010
3Long Noncoding RNAIBA
01/2023 - 01/2019
3Androgen Receptors (Androgen Receptor)IBA
01/2023 - 01/2014
3Checkpoint Kinase 1IBA
01/2023 - 01/2006
3taxaneIBA
12/2022 - 01/2015

Therapy/Procedure

63Therapeutics
05/2024 - 11/2004
36Drug Therapy (Chemotherapy)
12/2024 - 09/2002
21Immunotherapy
04/2024 - 06/2007
19Neoadjuvant Therapy
12/2023 - 08/2005
7Adjuvant Chemotherapy
02/2023 - 01/2013
5Precision Medicine
09/2022 - 01/2018
5Lymph Node Excision (Lymph Node Dissection)
09/2022 - 03/2013
5Radiotherapy
09/2021 - 08/2005
5Hysterectomy
01/2016 - 08/2005
4Transplantation
01/2023 - 09/2002